Special Issue

Novel Nanoparticle-Based Treatment and Imaging Modalities

Message from the Guest Editors

Over the last twenty years, nanomaterials have been widely used in cancer research. Numerous reports suggest that nanoparticles have the potential to improve conventional therapeutic (e.g., chemotherapy) and imaging (e.g., MRI) modalities for cancer detection and treatment. Nanomaterials allow further development of novel experimental treatment and imaging strategies, including photothermal therapy, magnetic hyperthermia, and photoacoustic imaging. In addition, though to a lesser extent, nanoparticle-based imaging and treatment modalities have frequently been explored for other nonmalignant diseases, such as pulmonary fibrosis, AIDS, muscular dystrophy, etc. The results of this research suggest that some fundamental principles of cancer nanomedicine could potentially be used for the development of novel nanoparticle-based strategies for treatment and imaging of other disorders. In this Special Issue, we invite authors to report their recently developed nanoparticle-based modalities for diagnosis and/or treatment of various disease states. We also welcome reviewer articles with expert opinions and perspectives in the nanomedicine field.

Guest Editors

Dr. Oleh Taratula

Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Portland, OR 97201, USA

Dr. Olena Taratula

Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Portland, OR, USA

Deadline for manuscript submissions

closed (20 May 2022)



an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/45911

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

